ラサギリン
参考資料

↑  “An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells”. Neuroscience Letters 326 (2):  105–8. (June 2002). doi:10.1016/s0304-3940(02)00332-4. PMID 12057839.
↑  “Rasagiline: a review of its use in the management of Parkinson's disease”. Drugs 67 (12):  1725–47. (2007). doi:10.2165/00003495-200767120-00006. PMID 17683172.
1 2 3  Richard B. Silverman, Mark W. Holladay.  The Organic Chemistry of Drug Design and Drug Action, 3rd Edition. Academic Press, 2014 ISBN 9780123820310
1 2  “Pharmacology and neuroprotective properties of rasagiline”. Journal of Neural Transmission. Supplementum 48:  95–101. (1996). doi:10.1007/978-3-7091-7494-4_9. PMID 8988465.
↑  “Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease”. CNS Drugs 22 (7):  563–86. (2008). doi:10.2165/00023210-200822070-00003. PMID 18547126.
1 2 3  “Rasagiline for the treatment of Parkinson's disease: an update”. Expert Opinion on Pharmacotherapy 16 (14):  2231–41. (2015). doi:10.1517/14656566.2015.1086748. PMID 26364897.
↑  “Therapeutic advances in multiple system atrophy and progressive supranuclear palsy”. Movement Disorders 30 (11):  1528–38. (September 2015). doi:10.1002/mds.26334. PMID 26227071.
1 2 3 4 5 6 7 8 9  Azilect Prescribing Information Label last revised May, 2014
↑  “From a Parkinson's disease expert: Rasagiline and the future of therapy”. Molecular Neurodegeneration 2 (1):  13. (July 2007). doi:10.1186/1750-1326-2-13. PMC 1929084. PMID 17617893. http://www.molecularneurodegeneration.com/content/pdf/1750-1326-2-13.pdf.
1 2 3  “Rasagiline”. Nature Reviews. Drug Discovery 4 (8):  625–6. (August 2005). doi:10.1038/nrd1803. PMID 16106586.
1 2  “パーキンソン病治療剤「アジレクト錠」の日本における製造販売承認取得について”. www.takeda.com. 2021年4月28日閲覧。
1 2 3 4  “アジレクト錠1mg／アジレクト錠0.5mg 添付文書”. www.info.pmda.go.jp.   PMDA. 2021年4月28日閲覧。
↑  “Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons”. The Journal of Pharmacology and Experimental Therapeutics 259 (2):  841–7. (November 1991). PMID 1658311.
1 2   Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. (2012). p. 434. ISBN 978-1609133450
↑  “Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline”. Neuroscience Letters 355 (3):  169–72. (January 2004). doi:10.1016/j.neulet.2003.10.067. PMID 14732458.
↑  “Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research”. Journal of Neural Transmission. Supplementum 48:  61–73. (1996-01-01). doi:10.1007/978-3-7091-7494-4_6. ISBN 978-3-211-82891-5. PMID 8988462.
↑  Chen, Jack J.; Swope, David M. (2005-08-XX). “Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease” (英語). The Journal of Clinical Pharmacology 45 (8):  878–894. doi:10.1177/0091270005277935. http://doi.wiley.com/10.1177/0091270005277935.
↑  “Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis”. Journal of Medicinal Chemistry 48 (26):  8148–54. (December 2005). doi:10.1021/jm0506266. PMC 2519603. PMID 16366596. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519603/.
↑  “Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy”. Therapeutics and Clinical Risk Management 3 (3):  467–74. (June 2007). PMC 2386362. PMID 18488080. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386362/.
↑  US 3,513,244.  See US patent 5453446, lines 50-60.  US Patent 5453446 was the patent at issue in Teva v Watson, see page 2
↑  “Making armor for the brain”. The Jerusalem Post (13 November 2010). 2021年4月29日閲覧。
↑  “アジレクト錠1mg／アジレクト錠0.5mg インタビューフォーム”.   PMDA. 2021年4月28日閲覧。
↑  “Therapeutic advances in multiple system atrophy and progressive supranuclear palsy”. Movement Disorders 30 (11):  1528–38. (September 2015). doi:10.1002/mds.26334. PMID 26227071.
↑  “FDA Advisers Refuse Teva Plea to Expand Azilect Label”. Reuters and Haaretz (19 October 2011). 2021年4月29日閲覧。
↑  “Peripheral and Central Nervous System Advisory Committee Background Package on Azilect”.   FDA. December 7, 2011閲覧。
(R)-1-アミノインダン